Basic study for regenerative medicine in muscular dystrophy by myogenic stem cells
肌源性干细胞再生医学治疗肌营养不良症的基础研究
基本信息
- 批准号:18590961
- 负责人:
- 金额:$ 2.49万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2006
- 资助国家:日本
- 起止时间:2006 至 2007
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Muscular dystrophies are inherited disorders characterized by severe muscular degeneration and regeneration, resulting in severe muscular weakness and disability in daily living. From the cloning of dystrophin, the gene deficient in Duchenne muscular dystrophy (DMD), many responsible genes for muscular dystrophies have been isolated and complex pathogenesis leading to these disorders have been partially clarified. Clinically safe and effective treatment of these disorders, however, has not been developed yet. Mesenchymal stem cells derived from bone marrow have shown to be a distinct population of myogenic stem cells. Here we investigated whether the bone marrow transplantation (BMT), which has been widely applied as a safe therapeutic tool for hematological disorders, become a therapeutic potential for muscular dystrophy. Total bone marrow cells from green fluorescent protein (GFP) mice have been isolated as donor cells. We transplanted these cells into two types of muscular dystrophy … More models; dystrophin-deficient DMD model mice (mdx) and laminin-α2-deficient congenital muscular dystrophy type 1A (MDC1A) model mice (dy). BMT failed to produce significant improvement in muscle performance and muscular pathology, except for the restoration of dystrophin in some GFP positive myofibers in the mdx mice. In sharp contrast, BMT has led to a significant increase of life span in the dy mice. Physiological function of muscles including respiratory muscles in the dy mice has significantly improved by BMT. Immunohistochemical analysis of diaphragm from the dy mice after BMT, exhibited that over 60% myofibers were GFP-positive and over 80% myofibers expressed laminin-α2. These findings gave rise to a possibility that some muscular dystrophies with basement membrane disruption, such as MDC 1A were more responsive to BMT than those with plasma membrane disruption, such as DMD. Thus we further investigated the efficacy of BMT on another mouse model of muscular dystrophy, Fukuyama type congenital muscular dystrophy (FCMD), which showed severe basement membrane disruption. Compared to the mdx mice, the FCMD model mice showed increased GFP-positive myofibers in diaphragm after BMT. Additionally, we found that a treatment of basement membrane disruption in muscles of wild-type mice significantly increased many GFP-positive myofibers after BMT. Our results may open the avenue for clinically safe and effective treatment for muscular dystrophy by BMT. Less
肌肉萎缩症是一种遗传性疾病,其特征是严重的肌肉退化和再生,导致严重的肌肉无力和日常生活残疾。从Duchenne肌营养不良症(DMD)的基因缺陷——肌营养不良蛋白(dystrophin)的克隆,分离出许多肌营养不良症的相关基因,部分阐明了导致这些疾病的复杂发病机制。然而,临床上安全有效的治疗这些疾病的方法尚未开发出来。骨髓间充质干细胞是一种独特的肌源性干细胞。在这里,我们研究骨髓移植(BMT)作为一种安全的血液系统疾病的治疗工具是否成为治疗肌肉萎缩症的潜在疗法。从绿色荧光蛋白(GFP)小鼠中分离出总骨髓细胞作为供体细胞。我们将这些细胞移植到两种类型的肌肉萎缩症中…肌营养不良蛋白缺陷型DMD模型小鼠(mdx)和层粘连蛋白-α2缺陷型1A型先天性肌营养不良模型小鼠(dy)。除了mdx小鼠中一些GFP阳性肌纤维中的肌营养不良蛋白恢复外,BMT未能对肌肉性能和肌肉病理产生显著改善。与之形成鲜明对比的是,BMT显著延长了小鼠的寿命。BMT显著改善了dy小鼠包括呼吸肌在内的肌肉生理功能。免疫组化分析显示,超过60%的肌纤维呈gfp阳性,超过80%的肌纤维表达层粘连蛋白-α2。这些发现表明,一些基底膜破坏的肌营养不良症(如MDC 1A)比质膜破坏的肌营养不良症(如DMD)对BMT的反应更敏感。因此,我们进一步研究了BMT对另一种肌营养不良小鼠模型Fukuyama型先天性肌营养不良(Fukuyama type congenital muscular dystrophy, FCMD)的疗效,Fukuyama型先天性肌营养不良表现为严重的基底膜破坏。与mdx小鼠相比,BMT后ffcmd模型小鼠膈肌gfp阳性肌纤维增加。此外,我们发现对野生型小鼠肌肉基底膜破坏的处理显著增加了BMT后许多gfp阳性肌纤维。我们的研究结果可能为临床安全有效地治疗肌营养不良开辟了道路。少
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Myostatin inhibition reverses satellite cell number in caveolin-3-deficient mouse muscle.
肌肉生长抑制素抑制可逆转 Caveolin-3 缺陷小鼠肌肉中卫星细胞的数量。
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Ohsawa Y;Sunada Y.
- 通讯作者:Sunada Y.
Involvement of Wnt4 Signaling During Myogenic Proliferation and Differentiation of Skeletal Muscle.
Wnt4 信号传导在骨骼肌的生肌增殖和分化过程中的参与。
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Takata H;Terada K;Oka H;Sunada Y;Moriguchi T;Nohno T
- 通讯作者:Nohno T
Therapeutic effects of small-molecule inhibitors of type I TGB-β receptors for the treatment of muscular dystrophy
I型TGB-β受体小分子抑制剂治疗肌营养不良症的疗效
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:Sunada Y;Ohsawa Y;Murakami T
- 通讯作者:Murakami T
TGF-βファミリーシグナルによる神経・筋疾患の制御.細胞39(8)26-30
TGF-β 家族信号控制神经肌肉疾病。细胞 39(8)26-30
- DOI:
- 发表时间:2007
- 期刊:
- 影响因子:0
- 作者:大沢 裕;砂田 芳秀
- 通讯作者:砂田 芳秀
Bone marrow transplantation improves outcome in a mouse model of congenital muscular dystrophy
- DOI:10.1016/j.febslet.2006.07.015
- 发表时间:2006-08-07
- 期刊:
- 影响因子:3.5
- 作者:Hagiwara, Hiroki;Ohsawa, Yutaka;Sunada, Yoshihide
- 通讯作者:Sunada, Yoshihide
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MURAKAMI Tatsufumi其他文献
MURAKAMI Tatsufumi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MURAKAMI Tatsufumi', 18)}}的其他基金
Basic study of neuroregenerative therapy for diabetic polyneuropathy
糖尿病多发性神经病神经再生治疗的基础研究
- 批准号:
23591260 - 财政年份:2011
- 资助金额:
$ 2.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study of gene therapy on hypoalgesia in sensory neuropathy using neurotrophic factors
神经营养因子对感觉神经病痛觉减退的基因治疗研究
- 批准号:
17590906 - 财政年份:2005
- 资助金额:
$ 2.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study of electro-gene therapy on diabetic neuropathy
电基因疗法治疗糖尿病神经病变的研究
- 批准号:
13670679 - 财政年份:2001
- 资助金额:
$ 2.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Prevention of age-related hearing loss using bone marrow transplantation
利用骨髓移植预防与年龄相关的听力损失
- 批准号:
23K08999 - 财政年份:2023
- 资助金额:
$ 2.49万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation
使用靶向骨髓照射治疗镰状细胞病的新型骨髓移植方法
- 批准号:
10737358 - 财政年份:2023
- 资助金额:
$ 2.49万 - 项目类别:
Tuning tyrosine kinase signalling to improve haematopoietic stem cell expansion and bone marrow transplantation
调节酪氨酸激酶信号传导以改善造血干细胞扩增和骨髓移植
- 批准号:
2889841 - 财政年份:2023
- 资助金额:
$ 2.49万 - 项目类别:
Studentship
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10722602 - 财政年份:2022
- 资助金额:
$ 2.49万 - 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10368246 - 财政年份:2022
- 资助金额:
$ 2.49万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10600143 - 财政年份:2022
- 资助金额:
$ 2.49万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10370775 - 财政年份:2022
- 资助金额:
$ 2.49万 - 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
- 批准号:
10415200 - 财政年份:2021
- 资助金额:
$ 2.49万 - 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
- 批准号:
10303678 - 财政年份:2021
- 资助金额:
$ 2.49万 - 项目类别:














{{item.name}}会员




